Serviços Personalizados
Journal
Artigo
nova página do texto(beta)
Espanhol (pdf)
Artigo em XML
Referências do artigo
Tradução automática
Enviar este artigo por emailIndicadores
-
Citado por SciELO -
Acessos
Links relacionados
-
Similares em
SciELO
Compartilhar
Permalink
Revista odontológica mexicana
versão impressa ISSN 1870-199X
Rev. Odont. Mex vol.12 no.3 Ciudad de México Set. 2008
https://doi.org/10.22201/fo.1870199xp.2008.12.3.15666
Trabajos originales
Toxina botulínica en la distonía muscular de la articulación temporomandibular
Botulinum toxin in muscular dystonia of the temporomandibular joint
*Residente de cuarto año. Servicio de Cirugía Maxilofacial del Hospital Regional 1º de Octubre. ISSSTE.
§Titular del Curso de Residencia. Servicio de Cirugía Maxilofacial del Hospital Regional 1º de Octubre. ISSSTE.
El objetivo de este estudio fue evaluar la eficacia de la toxina botulínica tipo A como terapéutica sintomática en pacientes con disfunción de articulación temporomandibular y distonia oromandibular de cierre. Se incluyeron 20 sujetos entre 29 y 61 años de edad, (90%) mujeres, (10%) hombres. Se infiltraron los puntos gatillo, se midió el dolor con la escala visual análoga del dolor (EVA) pre-infiltración y semanalmente durante 3 meses. La media en la EVA del dolor pre-tratamiento fue 8.15 puntos y postratamiento de 3.7 puntos, con mejoría del dolor del 45.3% efectiva y sostenida. Se propone un nuevo algoritmo terapéutico, con la toxina botulínica tipo A.
Palabras clave: Toxina botulínica tipo A; distonia oromandibular de cierre; articulación temporomandibular
This investigation evaluated the effectiveness of the botulinum toxin type A in patients with temporomandibular joint dysfunction and oromandibular closing dystonia. Twenty persons were included between 29 and 61 years old, (90%) women, (10%) men. The trigger points were infiltrated, the pre-infiltration pain was measured with the analogous visual scale of the pain (AVS) and also weekly during 3 months. The mean value in the AVS of the initial pain was 8.15 points and for post-infiltration, the mean value was 3.7 points, with improvement of the pain of 45.3%. A new treatment with the botulinum toxin type A is proposed.
Key words: Botulinum toxin type A; oromandibular closing dystonia; temporomandibular joint
REFERENCIAS
1. Marvin S, Brian F. Botulinum toxin a therapy for temporomandibular disorders. In: Brin Mitchell F, ed. Scientific and therapeutic aspects of botulinum toxin. Philadelphia PA: Lippincott Williams & Wilkins: 2002: 259-268. [ Links ]
2. Glenn T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Department of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA. Phys Med Rehabil Clin N Am 2003: 727-748. [ Links ]
3. Eng-Kin T, Ling-Ling C, Hui-Meng C. Severe bruxism following basal ganglia infarcts: insights into pathophysiology. J Neurol Sci 2004: 217(2): 229-32 2004010126 [ Links ]
4. Hyun J, Kwang-Won Y, Sam-Sun L, Min-Suk H, Kyle S. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 2003: 29(5): 484-9. [ Links ]
5. Marvin S, Brian F. The Crown Institute, Toronto, Ontario, Canada. Treatment of Temporomandibular Disorders with Botulinum Toxin. Clin J Pain 2002; 18 (6 Suppl): 5198-5203 ilkins, Inc., Philadelphia. [ Links ]
6. Ada T. Treatment of masseteric hypertrophy. In: Hexsel D, ed. Cosmetic use of botulinum toxin. 1 ed. São Paulo Brazil: age Editoria: 2002: 185-186. [ Links ]
7. Jeffrey A, Corinne H. Andrew B. Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg 2004: 6: 188-191. [ Links ]
8. Ron T, Joseph J. Botulinum Toxin Type A in the management of oromandibular dystonia and bruxism. In: Brin MF, ed. Scienti-fie and therapeutic aspects of botulinum. Toxin Philadelphia PA: Lippincott Williams & Wilkins: 2002: 343-350. [ Links ]
9. Joseph N., III, DDS. The use of botulinum toxin in cosmetic facial surgery. Oral and Maxillofacial Surgery Clinics of North America 2000. [ Links ]
10. Frank S, John M, James R. Treatment of severe post-traumatic bruxism with botulinum toxin-A: Case report. J Oral Maxillofac Surg 2002: 60: 115-117. [ Links ]
11. Joseph N. Botulinum toxin A: A review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003; 61: 317-324. [ Links ]
12. Martinez P, Ruiz E. Recurrent temporomandibular joint disio-cation treated with botulinum toxin: Report of 3 cases. J Oral Maxillofac Surg February 2004: 62(2). [ Links ]
13. Herzog W, Leonard TR. The history dependence of force production in mammalian skeletal muscle following stretch-shortening and shortening-stretch cycles. Journal of Biomechanies 2000; 33: 531-542. [ Links ]
14. Quartaronea A, Girlanda P, Di Lazzaro V, Majorana G, Battaglia F, Messina C. Short latency trigemino-sternocleidomastoid response in muscles in patients with spasmodic torticollis and blepharospasm. Clinical Neurophysiology 2000; 111: 1672-1677. [ Links ]
15. Hussain G, Manktelow RT, Tomat LR. Depressor labii inferioris resection: an effective treatment for marginal mandibular nerve paralysis. The British Association of Plastic Surgeons 2004; 57: 502-510. [ Links ]
16. de Séze MP, de Séze M, Dehail P, Joseph PA, Lavignolle B, Barat M, Mazaux JM. Toxine botulique A et douleurs museu-losqueletiques. Botulinum toxin A and musculoskeletal pain. Service de medicine physique et de readaptation, hospital Tastet-Girard-Pellegrin, CHU de Bordeaux France. Available online 13 August 2003. [ Links ]
17. Dirk D. Prólogo de Michel F. Masson Doyma México. 1er Ed. 2003. Tratamiento con toxina botulínica. [ Links ]
18. Jeffre P. 4a Ed. Harcourt brace 1999 España. Tratamiento de oclusión y afecciones temporomandibulares. [ Links ]
19. Christopher F. Clinical Applications Botulinum Toxin: Implications for Pain Management. [ Links ]
20. Welden B. Clinical management of temporomandibular disorders. Year Book Medical Publishers, Inc. Chicago London. 1er ed. 1982. [ Links ]
21. Stephen B. Chronic temporomandibular joint arthralgia. Oral and Maxillofacial Surgery Clinics of North America. [ Links ]
22. Hartmut G. Botulinum toxin A in pain management: Mechanisms of action and rationale for optimum use. In: Jost WH (ed): Botulinum toxin in painful diseases. Pain Headache. Basel, Karger, Kiel Pain Clinic, Kiel, Germany. 2003; 14: 14-22. [ Links ]
23. Christopher R. Clinical Applications of Botulinum Toxin: Implications for Pain Management. Colorado Neurological Institute, Englewood, Colorado, USA. Pain Digest 1998; 8(6): 342-345. [ Links ]
24. Mitchell F, William B, Andrew B, Lawrence S, Janice M. Botu-Unum toxin type A Botox(r) for pain and headache. Philadelphia PA: Lippincott Williams & Wilkips; 2002: 233-250. [ Links ]
25. López del V, Castro G. Toxina botulínica: Aplicaciones terapeuticas. Masson. 1 Ed. 2002. [ Links ]
26. Bell WE. Temporomandibular disorders, ed 3, Chicago. Year Book Medical Publishers. 1990: 60-61. [ Links ]
27. Christensen LV, Mohamed SE, Harrison JD. Delayed onset of masseter muscle pain in experimental tooth clenching. J Prosthetic Dent 1982; 48(5): 579-84. [ Links ]
28. Laskin DM. Etiology of the pain-dysfunction syndrome. J Am Dent Assoc 1969; 79(1): 147-53. [ Links ]
29. Traveil JG, Rinzler SH. The myofascial genesis of pain. Post Grad Medi 952:11: 425-34. [ Links ]
30. Simons DG, Traveil JG. Myofascial trigger points, a possible, explanation. Pain 1981; 10(1): 106-9. [ Links ]
Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons
